Description: Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The Company has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. It is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. It is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.
Home Page: www.amarantus.com
45 Wall Street
New York,
NY
10005
United States
Phone:
650-862-5391
Officers
| Name | Title |
|---|---|
| Mr. Gerald E. Commissiong | CEO, Pres & Director |
| Dr. John Wesley Commissiong | Chief Scientific Officer, Director & Member of Scientific Advisory Board |
| Mr. Robert Lewis Harris | Compliance Officer & Director |
| Dr. Elise Brownell M.S., Ph.D. | Sr. VP of Operations & Project Management |
| Aimee Boutcher | Director of Investor Relations |
| Dr. Ravi Kiron | Sr. VP of Bus. Devel. |
| Dr. Paula T. Trzepacz M.D. | Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics |
| Dr. Brian E. Harvey | Chief Regulatory Advisor & Member of Board of Advisors |
| Dr. Richard Kagan M.D. | Chief Medical Advisor to Cutanogen Corp. |
| Dr. Owen Garrick | Corp. Advisor |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 53.1851 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |